KTTA Stock Catalyst: Pasithea Therapeutics Announces Preclinical Data on PAS-004

May 19, 2025 · 7:50pm ET

PAS-004 shows inhibition of ETS2 signaling, a key driver of inflammation.

Max move

+56.9%

High of day $1.44

Sparker timei

7:50pm ET

KTTA · May 19, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Pasithea Therapeutics Corp. (Nasdaq: KTTA) announced on May 20, 2025, that preclinical data demonstrated PAS-004 inhibits ETS2 signaling, which is a significant driver of inflammation in inflammatory bowel disease (IBD) and other large addressable market diseases.

The announcement highlighted that PAS-004's mechanism of action compares favorably to selumetinib, indicating potential therapeutic benefits.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time KTTA sparks.

Download Sniper App →

Catch the next KTTA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →